At last, a gene therapy for Parkinson's disease?

Affiliations

Comment

Michael Hutchinson. Lancet Neurol. 2011 Apr.

. 2011 Apr;10(4):290-1.

doi: 10.1016/S1474-4422(11)70041-2.

¹ New York University School of Medicine, New York, NY 10016, USA. michael.hutchinson@nyumc.org

No abstract available

Comment on

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.
LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A. LeWitt PA, et al. Lancet Neurol. 2011 Apr;10(4):309-19. doi: 10.1016/S1474-4422(11)70039-4. Lancet Neurol. 2011. PMID: 21419704 Clinical Trial.